CHRO
Channel
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CHRO
Channel Therapeutics Corporation
Biopharmaceutical company treating erythromelalgia
Biological Technology
03/19/2021
02/16/2024
American Stock Exchange
4
12-31
Common stock
4400 Route 9 South, Suite 1000, Freehold, NJ 07728
--
Channel Therapeutics Corporation was incorporated in Nevada on March 19, 2021. The company is a clinical-stage biotechnology company focused on developing and commercializing new therapies for pain relief. The company's clinical focus is selectively targeting sodium ion channels, known as "NaV 1.7," as well as other receptors in the NaV family. NaV 1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with some kind of hereditary NaV 1.7 regulation consistently show pathology of not feeling pain.
Company Financials
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
